MASLD risk in breast or colorectal cancer survivors
Part of Cancer, Hormones & metabolism clinical trials.
This study looks at whether breast or colorectal cancer survivors are more likely to develop a liver condition called MASLD (fatty liver disease not caused by alcohol). It uses blood tests, imaging, and possibly an MRI to check liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had breast or colorectal cancer at least 5 years ago, but not more than 10 years ago.
- You have not had the cancer come back or been diagnosed with a new cancer (except for certain minor skin or bladder cancers).
- You are 18 or older.
- You agree to sign a consent form.
- You do not have known or suspected chronic liver disease.
- For the MRI portion, you have no metal implants, devices, or other reasons you cannot have an MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study looks at how a specific gene (PNPLA3) might affect non-alcoholic fatty liver disease (MASLD) in people from Guadeloupe, French Guiana, and Réunion Island. It aims to understand genetic differences that could explain why some people get the disease.
This study aims to understand the genetic factors behind metabolic fatty liver disease (MASLD) by comparing patients with advanced liver scarring or liver cancer to healthy blood donors. It may help doctors better predict and treat the disease in the future.
This study is testing whether an MRI can help doctors see liver scarring (fibrosis) in people with MASLD, a type of fatty liver disease. It is for patients who already need a liver biopsy as part of their care, to compare the MRI results with the biopsy.
This study looks at factors that predict liver cancer and the need for a liver transplant in people with a liver condition called MASLD (metabolic dysfunction-associated steatotic liver disease). The goal is to better understand the disease and improve care.
This trial tests if a supplement called SAMe can help prevent liver cancer in people with cirrhosis caused by MASLD (a fatty liver disease linked to metabolic issues). If you have MASLD, cirrhosis, and certain risk factors like diabetes or high blood pressure, you may be able to join.
Hear when a new Breast Cancer Survivors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.